[Complete auriculoventricular block in a patient treatment with Lopinavir/Ritonavir].
Jiménez
Fermín J
FJ
Pinilla
Javier
J
Repiso
Manuel
M
Labarga
Pablo
P
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D023241:Antiretroviral Therapy, Highly Active; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002037:Bundle-Branch Block / Q000150:complications; D051544:Cytochrome P-450 CYP3A; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006327:Heart Block / Q000139:chemically induced* / Q000209:etiology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors / Q000378:metabolism; D011744:Pyrimidinones / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D013575:Syncope / Q000209:etiology; D015215:Zidovudine / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D019259:Lamivudine; D015215:Zidovudine; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating; D019438:Ritonavir